Foveal cone loss in tamoxifen maculopathy: a case report

J Med Case Rep. 2023 Nov 8;17(1):464. doi: 10.1186/s13256-023-04199-z.

Abstract

Background: Tamoxifen is used in low dose concentrations (20-40 mg per day) as a therapy for breast cancer but is known to have ocular side effects. In this case report, the foveal cone integrity in a tamoxifen-treated patient who complained of a small central scotoma in the left eye while reading was examined using high resolution adaptive optics imaging.

Case presentation: Both eyes of a 54-year-old Caucasian, non-hispanic female who had been treated with tamoxifen for 1.5 years were examined using various imaging modalities including fundus photography, fundus autofluorescence, fluorescein angiography, spectral-domain optical coherence tomography, and adaptive optics scanning laser ophthalmoscopy. Clinical spectral-domain optical coherence tomography showed a very small disruption to the photoreceptor layer at the fovea in the left eye only. However, adaptive optics scanning laser ophthalmoscopy imaging revealed foveal cone loss in both eyes, but to a lesser extent in the right eye. Inner retinal changes were not observed in either eye.

Conclusion: The area of cone loss was similar in size to a single newsprint letter when projected onto the retina, matching the patient's description of a scotoma in the left eye. Given the isolated loss of foveal cone photoreceptors with the absence of previously reported inner retinal and vascular changes, our results may indicate the earliest retinal changes associated with tamoxifen retinopathy.

Keywords: Adaptive optics; Cone photoreceptors; Imaging; Retina; Scanning laser ophthalmoscopy; Tamoxifen maculopathy.

Publication types

  • Case Reports

MeSH terms

  • Female
  • Fluorescein Angiography / methods
  • Humans
  • Macular Degeneration*
  • Middle Aged
  • Retinal Cone Photoreceptor Cells
  • Retinal Diseases* / chemically induced
  • Retinal Diseases* / diagnostic imaging
  • Scotoma
  • Tamoxifen / adverse effects
  • Tomography, Optical Coherence / methods

Substances

  • Tamoxifen